Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 13/20 | 0.68 |
| ▸ | FPR1 | P21462 | 1/20 | 0.68 |
| ▸ | GPR183 | P32249 | 1/20 | 0.68 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264070 | 0.92 | GNRHR (0.57) | GNRHRFPR1GPR183GPR119ALDH1A1 | |
| SCHEMBL5267626 | 0.92 | GNRHR (0.56) | GNRHRFPR1GPR183GPR119ALDH1A1 | |
| SCHEMBL5705276 | 0.92 | GNRHR (0.71) | GNRHRFPR1GPR183GPR119ALDH1A1 | |
| SCHEMBL5266205 | 0.88 | GNRHR (0.71) | GNRHRFPR1GPR183GPR119ALDH1A1 | |
| SCHEMBL5269071 | 0.84 | GNRHR (0.51) | GNRHRFPR1GPR183GPR119ALDH1A1 | |
| SCHEMBL5265665 | 0.83 | GNRHR (0.55) | GNRHRFPR1GPR183GPR119ALDH1A1 | |
| SCHEMBL5264580 | 0.82 | GNRHR (0.49) | GNRHRFPR1GPR183GPR119ALDH1A1 | |
| SCHEMBL208907 | 0.81 | GNRHR (1.00) | GNRHRFPR1GPR183GPR119 | |
| SCHEMBL31060713 | 0.81 | GNRHR (1.00) | GNRHRFPR1GPR183GPR119 | |
| SCHEMBL5834658 | 0.81 | GNRHR (0.82) | GNRHRFPR1GPR183GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648906-B1 | ORGANOSILICON COMPOUNDS AND THEIR USE | TAKEDA CAMBRIDGE LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| US-20070111967-A1 | Organosilicon compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-17 | — | — | US | claimed |
| EP-1648906-B1 | ORGANOSILICON COMPOUNDS AND THEIR USE | TAKEDA CAMBRIDGE LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| EP-1648906-B1 | ORGANOSILICON COMPOUNDS AND THEIR USE | TAKEDA CAMBRIDGE LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20070111967-A1 | Organosilicon compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070111967-A1 | Organosilicon compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1648906-A1 | ORGANOSILICON COMPOUNDS AND THEIR USE | Paradigm Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005005443-A1 | ORGANOSILICON COMPOUNDS AND THEIR USE | PARADIGM THERAPEUTICS LTD. (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111967-A1 | Organosilicon compounds and their use | CYP2B6, UGT1A6, CYP2D6 | GNRHR 2847/4885FPR1 509/4885GPR183 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.